Stocks and Investing
Stocks and Investing
Thu, March 2, 2023
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Yigal Nochomovitz Maintained (SNDX) at Strong Buy with Increased Target to $32 on, Mar 2nd, 2023
Yigal Nochomovitz of Citigroup, Maintained "Syndax Pharmaceuticals, Inc." (SNDX) at Strong Buy with Increased Target from $29 to $32 on, Mar 2nd, 2023.
Yigal has made no other calls on SNDX in the last 4 months.
There are 4 other peers that have a rating on SNDX. Out of the 4 peers that are also analyzing SNDX, 0 agree with Yigal's Rating of Hold.
These are the ratings of the 4 analyists that currently disagree with Yigal
- Edward White of "HC Wainwright & Co." Reiterated at Strong Buy and Held Target at $33 on, Wednesday, March 1st, 2023
- Madhu Kumar of "Goldman Sachs" Maintained at Strong Buy with Decreased Target to $34 on, Wednesday, March 1st, 2023
- Bradley Canino of "Stifel" Initiated at Strong Buy and Held Target at $37 on, Tuesday, January 31st, 2023
- Anupam Rama of "JP Morgan" Initiated at Buy and Held Target at $41 on, Tuesday, January 3rd, 2023
Contributing Sources